<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of pharyngitis due to group A &lt;em&gt;Streptococcus&lt;/em&gt; in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of pharyngitis due to group A <em>Streptococcus</em> in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of pharyngitis due to group A <em>Streptococcus</em> in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Antibiotic class</td> <td class="subtitle1">Drug</td> <td class="subtitle1">Dosing in adults<sup>*</sup></td> <td class="subtitle1">Advantages</td> <td class="subtitle1">Disadvantages</td> </tr> <tr> <td class="divider_bottom" rowspan="3"><strong>Penicillins</strong><br/> (preferred)</td> <td>Penicillin V</td> <td> <ul> <li>500 mg orally two to three times daily for 10 days</li> </ul> </td> <td> <ul> <li>Narrow spectrum</li> <li>No documented resistance</li> <li>Low cost</li> </ul> </td> <td> <ul> <li>Three-times-daily dosing; however, twice-daily regimen appears to be as effective as thrice daily<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td>Amoxicillin<sup>¶</sup></td> <td> <ul> <li>500 mg orally twice daily for 10 days</li> <li>1000 mg (immediate release) once daily for 10 days</li> </ul> </td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td>Penicillin G benzathine<sup>*</sup><br/> (Bicillin L-A)</td> <td> <ul> <li>1.2 million units IM as a single dose</li> </ul> </td> <td> <ul> <li>Can be given as a single dose</li> <li>Ensured adherence</li> <li>Only drug studied for prevention of acute rheumatic fever</li> </ul> </td> <td> <ul> <li>Variable availability</li> <li>High cost</li> <li>Injection site pain</li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="5"><strong>Cephalosporins</strong><br/> (potential alternatives for mild reactions to penicillin<sup>Δ</sup>)</td> <td>Cephalexin<sup>*</sup><br/> (first generation)</td> <td> <ul> <li>500 mg orally twice daily for 10 days</li> </ul> </td> <td> <ul> <li>High efficacy rate</li> <li>Narrower spectrum than later-generation cephalosporins</li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin</li> <li>Greater potential to induce antibiotic resistance</li> </ul> </td> </tr> <tr> <td>Cefadroxil<sup>*</sup> (first generation)</td> <td> <ul> <li>1 g orally daily for 10 days</li> </ul> </td> <td> <ul> <li>Once daily</li> <li>High efficacy rate</li> <li>Narrower spectrum than later-generation cephalosporins</li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin</li> <li>Greater potential to induce antibiotic resistance</li> </ul> </td> </tr> <tr> <td>Cefuroxime<sup>*</sup><br/> (second generation)</td> <td> <ul> <li>250 mg orally twice daily for 10 days</li> </ul> </td> <td> <ul> <li>High efficacy rate</li> <li>Narrower spectrum than later-generation cephalosporins</li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and first-generation cephalosporins</li> <li>Greater potential to induce antibiotic resistance</li> </ul> </td> </tr> <tr> <td>Cefpodoxime<sup>*</sup><br/> (third generation)</td> <td> <ul> <li>100 mg orally twice daily for 5 to 10 days</li> </ul> </td> <td> <ul> <li>High efficacy rate</li> <li>FDA approved for 5-day course</li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and earlier-generation cephalosporins</li> <li>Greater potential to induce antibiotic resistance</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Cefdinir<sup>*</sup><br/> (third generation)</td> <td> <ul> <li>300 mg orally twice daily for 5 to 10 days or 600 mg orally once daily for 10 days</li> </ul> </td> <td> <ul> <li>Once-daily option</li> <li>High efficacy rate</li> <li>FDA approved for 5-day course</li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and earlier-generation cephalosporins</li> <li>Greater potential to induce antibiotic resistance</li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>Macrolides</strong><br/> (alternatives for patients with anaphylaxis or other IgE-mediated reactions or severe delayed reactions to penicillin<sup>Δ</sup>)</td> <td>Azithromycin</td> <td> <ul> <li>12 mg/kg/day (maximum 500 mg/dose) 5 days<sup>◊</sup></li> </ul> </td> <td> <ul> <li>Once daily</li> </ul> </td> <td> <ul> <li>Growing rates of resistance</li> <li>Associated with QTc prolongation and, rarely, life-threatening cardiovascular events including TdP; assess risk (eg, history of long QT interval, interacting medications, electrolyte abnormalities)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Clarithromycin<sup>*</sup></td> <td> <ul> <li>250 mg orally twice daily for 10 days</li> </ul> </td> <td> </td> <td> <ul> <li>Growing rates of resistance</li> <li>Greater gastrointestinal side effects than azithromycin</li> <li>Causes CYP3A4 drug interactions</li> <li>QTc prolongation: Refer to azithromycin</li> </ul> </td> </tr> <tr> <td><strong>Lincosamides</strong><br/> (alternative when macrolide resistance is a concern and penicillins and cephalosporins cannot be used)</td> <td>Clindamycin<sup>§</sup></td> <td> <ul> <li>300 mg orally three times daily for 10 days</li> </ul> </td> <td> </td> <td> <ul> <li>Growing rates of resistance</li> <li>High side-effect profile (ie, gastrointestinal)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>FDA: US Food and Drug Administration; IM: intramuscularly; TdP: torsades de pointes.</p>
<p>* Dose alteration may be needed for renal insufficiency.</p>
<p>¶ Once-daily immediate-release amoxicillin appears to be non-inferior to penicillin V or amoxicillin administered in multiple daily doses, primarily based on studies in children and adolescents.</p>
<p>Δ Approach to patients with penicillin allergy varies among experts and allergy severity; refer to the UpToDate text for additional detail.</p>
<p>◊ A 3-day course is approved and widely prescribed in Europe and other regions.</p>
§ Rates of resistance to clindamycin are high and can be higher than rates of resistance to macrolides. Therefore, when beta-lactams and macrolides cannot be used, knowledge of local resistance rates should guide antibiotic selection or culture with susceptibility testing should be obtained.</div><div class="graphic_reference">Reference:
<ol>
<li>Lan AJ, Colford JM, Colford JM Jr. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A meta-analysis. Pediatrics 2000; 105:E19.</li>
</ol>
<p class="extra_spacing_top">Data from:</p>
<ol>
<li>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of Group A Streptococcal pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:e86.</li>
<li>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: A scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.</li>
</ol></div><div id="graphicVersion">Graphic 64596 Version 47.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
